Exelixis Inc (EXEL) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Total Revenue Chart for Exelixis Inc

Exelixis Inc (EXEL) revenue for FY2025 was USD 2.3B, a 7.0% change from FY2024. Exelixis Inc's revenue grew from USD 2.3M in 1998 to USD 2.3B in 2025 (102018.2% over 27 years). Earnings per share grew from USD 0.58 in 2011 to USD 0.56 in 2022 (-3.2%). Revenue compound annual growth rate: 5-year CAGR of 18.6%, 10-year CAGR of 51.2%, 20-year CAGR of 18.6%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$14.45B
Implied Share Price
$58.33
Enterprise Value
$13.38B
Revenue (TTM)
$2.44B
EBITDA
$1.02B
Profit Margin
35.33%
Trailing P/E
18.58
Forward P/E
13.55
Price/Book (MRQ)
7.82
Price/Sales (TTM)
5.93
EV/EBITDA
13.11
EV/Revenue
5.49
Dividend Yield
—
Book Value
$7.41
Free Cash Flow (FY2025)
$844.34M
Free Cash Flow Yield
5.84%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.